Basic Information
| LncRNA/CircRNA Name | FAL1 |
| Synonyms | FALEC, FAL1, LINC00568, ncRNA-a1 |
| Region | GRCh38_1:150515757-150518032 |
| Ensemble | ENSG00000228126 |
| Refseq | NR_051960 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blot analysis |
| Sample | Human osteosarcoma cell lines (U2OS, HOS, SAOS??, 143B, and SW1353 cells from female patients and MG??3 cells from a male patient) and human osteoblast cell lines (hFOB1.19 and NHOst), The osteosarcoma specimens and matched nontumor tissues, osteosarcoma blood samples |
| Expression Pattern | up-regulated |
| Function Description | FAL1 expression was significantly upregulated in human osteosarcoma tissues and cell lines compared with their normal controls. FAL1 expression level was positively correlated with the distance metastasis (P?=?.008) and tumor stage ( P?=?.013).our study showed that lncRNA FAL1 exhibits an important pro-oncogenic effect on osteosarcoma progression by targeting EMT, which may serve as a potential therapeutic target for osteosarcoma. |
| Pubmed ID | 29987852 |
| Year | 2018 |
| Title | LncRNA FAL1 is a negative prognostic biomarker and exhibits pro-oncogenic function in osteosarcoma. |
External Links
| Links for FAL1 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |